Last reviewed · How we verify

NCT05235217

Bioequivalence Study of Esomeprazole in Healthy Adult Subjects Under Fasting Condition

Completed Phase 1 Last updated 11 February 2022
What this trial tests

Phase 1 trial testing Test product (T) 40 mg Hard Gelatin Capsules in Bioequivalence in 32 participants. Completed in 18 June 2021.

Timeline
3 June 2021
Primary endpoint
18 June 2021
18 June 2021

Quick facts

Lead sponsorFuture University in Egypt
PhasePhase 1
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingnone
Primary purposehealth services research
Enrollment32
Start date3 June 2021
Primary completion18 June 2021
Estimated completion18 June 2021
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Future University in Egypt

Who can join

Adults 18 to 44, male only, with Bioequivalence. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The current study is conducted to evaluate and compare the relative bioavailability for Esomeprazole in two different products containing 40 mg Esomeprazole after a single oral dose administration under fasting conditions.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Bioequivalence

Currently open trials in the same condition.

Other Future University in Egypt trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05235217.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing